Adult Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Advanced Favorable Hodgkin Lymphoma
Drug combinations described in this section include the following:ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine.CEC: cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin.MOPP: mechlorethamine, vincristine, procarbazine, and prednisone.MOPP/ABV hybrid: mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, and vinblastine.Stanford V: doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone.MOPPEBVCAD: mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine.Patients are designated as having advanced favorable Hodgkin lymphoma (HL) if they have clinical stage III or stage IV disease and three or fewer risk factors on the International Prognostic Index for HL, which corresponds to a freedom-from-progression at greater than 80% at 5 years with combination
Complementary and Alternative Medicine in Cancer Treatment (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Overview
Complementary and alternative medicine (CAM) is a group of diverse medical and health care systems,practices,and products that are not presently considered to be part of conventional medicine (see Question 1). It is important that the same scientific evaluation that is used to assess conventional approaches be used to evaluate CAM therapies (see Question 3). The National Cancer Institute and ...
Endometrial Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (02 / 15 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Paranasal Sinus and Nasal Cavity Cancer
Recurrent paranasal sinus and nasal cavity cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the paranasal sinuses and nasal cavity or in other parts of the body.
Gastrointestinal Carcinoid Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with gastrointestinal carcinoid tumors. Different types of treatment are available for patients with gastrointestinal carcinoid tumor. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment. Four types of standard treatment are used:Surgery Treatment of GI carcinoid tumors usually includes surgery. One of the following surgical procedures may be used: Endoscopic resection: Surgery to remove a small tumor that is on the inside lining of the GI tract. An
Kaposi Sarcoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (09 / 19 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000258000-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Acute Myeloid Leukemia Treatment
Depression (PDQ®): Supportive care - Health Professional Information [NCI] - Pediatric Considerations for Depression
There is limited information concerning the incidence of depression in healthy children. One study of children seen in a general practice showed that 38% had problems that required major intervention by a psychiatrist. Another study of children aged 7 to 12 years showed a 1.9% incidence of depression. If applied to the general population of the United States, these results show that 40,000 12-year-olds are depressed. Teachers have estimated that as many as 10% to 15% of their students are depressed. The Joint Commission on Mental Health of Children states that 1.4 million children younger than 18 years need immediate help for disorders such as depression; only one-third of these children receive help for their disorder.Most children cope with the emotional upheaval related to cancer and demonstrate not only evidence of adaptation but positive psychosocial growth and development. A minority of children, however, develops psychological problems including depression, anxiety, sleep
Changes to This Summary (05 / 14 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. General Information About Adult Brain TumorsRevised text on factors used to diagnose brain metastases to include diagnostic procedures, including contrast magnetic resonance imaging (MRI) of the brain.Treatment Option OverviewAdded text to state that external-beam radiation therapy using either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy is considered an acceptable technique in radiation therapy delivery. Typically 2- to 3-cm margins on the MRI-based volumes to create the planning target volume are used. Dose escalation using radiosurgery has not improved outcomes.Added Souhami et al. as reference 15.Added Leptomeningeal carcinomatosis as a new subsection.Added text to state that a phase III randomized trial compared adjuvant whole-brain radiation therapy
Anal Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
Stage 0 (Carcinoma in Situ)Treatment of stage 0 is usually local resection.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 anal cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.Stage I Anal CancerTreatment of stage I anal cancer may include the following:Local resection.External-beam radiation therapy with or without chemotherapy. If cancer remains after treatment, more chemotherapy and radiation therapy may be given to avoid the need for a permanent colostomy.Internal radiation therapy.Abdominoperineal resection, if cancer remains or comes back after treatment with radiation therapy and chemotherapy.Internal radiation therapy for cancer that remains after treatment with external-beam radiation therapy.Patients who have had